ADH

Type: Public
On the web: http://www.adherex.com

Working nimbly with a very sticky subject, Adherex Technologies researches and develops cancer treatments. One of its lead drug candidates targets a tumor's blood supply and makes those blood vessels weak and leaky by disrupting a key protein. Other potential therapies could make cancer cells more vulnerable to anti-cancer drugs or help prevent hearing loss in children undergoing certain types of chemotherapy. Adherex Technologies' pipeline is strongly based on compounds that disrupt cadherins, proteins that adhere similar molecules together in cell adhesion. Southpoint Capital Advisors owns a controlling stake in the company.

Key numbers for fiscal year ending December, 2011:
Sales: $0.0M
Net income: $4.7M

Officers:
Chairman: Robert W. Butts
CEO and Director: Rosty Raykov
VP, CFO, and Director: Robert Andrade

Competitors:
AstraZeneca
OXiGENE
Roche Holding